High level latest statement: Welcome Indian pharmaceutical enterprises to invest and cooperate in China! What is the status quo of Indian pharmaceutical companies in China?

On October 12, 2019, at the second informal meeting of the leaders of China and India, the top leaders of the state put forward several suggestions, which clearly stated that "deepen practical cooperation and tighten interest ties" We should take the establishment of a high-level economic and trade dialogue mechanism as an opportunity to strengthen the docking of economic development strategies between the two countries and explore the establishment of a manufacturing partnership We welcome Indian pharmaceutical and information technology enterprises to invest and cooperate in China " In the previous second round of belt purchase, Dr redI, an Indian pharmaceutical company, brought olanzapine to the competition field At the kick-off meeting held on October 8-11, there were also opportunities from Indian pharmaceutical companies to actively seek cooperation with China on the spot.. It is an inevitable trend for Indian pharmaceutical companies to enter China no matter from market or policy Before 2018, India's import to China was mainly the OEM of APIs or preparations But just last July, Indian generics ushered in a turning point On July 9, 2018, Chinese Foreign Ministry spokesperson Hua Chunying said that China and India had a good communication on promoting Indian drugs to enter the Chinese market and carrying out dialogue, exchange and cooperation in the pharmaceutical industry between China and India Subsequently, Indian pharmaceutical companies accelerated their entry into China, and a number of generic pharmaceutical giants successively entered the Chinese market One year has passed, the bilateral pharmaceutical trade cooperation between China and India has gradually improved, and Indian drugs are gradually entering the Chinese market So what is the current situation of Indian pharmaceutical companies in China? 1 Mylan mylan is one of the world-class multinational pharmaceutical companies It has branches in New York and other places in the United States, with more than 30000 employees, half of which are in India Meilan products include many dosage forms of brand drugs and generic varieties, and are sold to 165 countries or regions around the world Before 2018, mylan entered China mainly as a production plant of Abbott, and its products on the market include fluvoxamine maleate tablets, itopride hydrochloride tablets, ipsartan tablets, pinaverium bromide tablets and mebeveline hydrochloride tablets In 2018, mylan and Guangzhou Bairui and Guangzhou Anxin respectively registered two APIs, Vium carbonate and esmeralazole magnesium, and in 2019 and Bono (Tianjin) registered the API of tormoxitine hydrochloride Among the one-off imports, in 2019, Dalian Kexiang purchased kabaratin of mylan In terms of preparations, in 2019, mylan, bioconlimited and meixinmeida medical information from India jointly declared trastuzumab for injection In August 2019, Pfizer officially announced a final agreement with the generic giant mylan, and its non patent drug brands and generic entity Upjohn will merge with mylan to create a new global pharmaceutical company After the merger, Pfizer shareholders will own 57% of the shares of the new company after the merger, while mylan shareholders will own 43% of the shares Pfizer is the first foreign enterprise to set up a global management team in China It only settled in Shanghai, China in May 2019 In 2018, Pfizer's turnover was 12.5 billion US dollars, and that in Greater China was 2.4 billion US dollars The merger of Meilan and Pfizer is likely to start in China, and Meilan can take the opportunity to enter China 2, NATCO NATCO is a rising star of Indian pharmaceutical enterprises, headquartered in Hyderabad, India, with a large number of products The main drugs most familiar to domestic patients are lung cancer targeted drugs (Iressa) and Elotinib hydrochloride (Troika), liver cancer targeted drugs (dorgime) and imatinib (Gleevec) used by leukemia patients, that is, I am not the God of medicine movie Indian medicine NATCO registered imatinib mesylate in 2017 and gefitinib API in 2018 and Shanghai Huayuan In 2019, NATCO cooperated with Shanghai Huayuan and Jiangsu Fosun to register lanthanum carbonate and zoledronic acid respectively In 2006, NATCO cooperated with the lambashi laboratory and Guangzhou Nanxin to apply for itraconazole injection, but it was not approved In March 2019, it was reported that NATCO would cooperate with Chinese institutions to start the clinical trial of gefitinib In view of the current declaration of imported generic drugs in category 5.2 and the implementation of the domestic clinical acquiescence system in October 2018, the be study of imported generic drugs has changed from the acquiescence system, but no information about the declaration of gefitinib by NATCO has been found According to Xianda data v3.5, in August 2019, NATCO, Hangzhou tiger and Jiangsu Durui respectively declared azacytidine for injection and Lanthanum Carbonate Chewable Tablets 3 Cipla siplacipra pharmaceutical factory was founded in 1935 It is an international pharmaceutical company and one of the top pharmaceutical companies in India It has a high reputation in the world Sipura is the world's largest manufacturer of antiretroviral drugs In 2012, simpra launched lamivudine tablets in China, and in 2017, bringer ingelhand telmisartan amlodipine tablets were manufactured by simpra and successfully launched in China The cooperation between xipra and China is relatively early As early as 2004, xipra and Shanghai chuano Pharmaceutical Group jointly established Jiangsu Xidi Pharmaceutical Co., Ltd Jiangsu hidi has successively declared Budesonide aerosol, compound ipratropium bromide aerosol, irinotecan hydrochloride injection, gemcitabine, carboplatin and carboplatin hydrochloride injection for injection, oxaliplatin and oxaliplatin injection, capecitabine and capecitabine tablets, ulinastate acetate, mainly products in the field of respiration and tumor, but only irinotecan hydrochloride injection The injection was approved for marketing in China in 2012, while the rest of the products have not been approved yet Budesonide aerosol was withdrawn in the clinical self-examination and verification In 2014, sipura sold its shares and quit the joint venture, and Jiangsu Xidi changed its name to Jiangsu chuangnio In 2018, sipura and Rundong pharmaceutical filed the APIs of formoterol fumarate dihydrate, fluticasone propionate and salmeterol cinnabate On July 16, 2019, cipraeu, the European branch of Indian pharmaceutical giant sipura, took the lead in announcing the establishment of a branch in China The branch will establish a joint venture with Jiangsu chuano Pharmaceutical Co., Ltd with a joint investment of US $30 million, focusing on respiratory products Sipura will invest 80% of the capital and hold 80% of the shares of the joint venture Once again, sipura set out in China without knowing whether more products could enter China smoothly this time 4 Sun Pharma is the fourth largest professional generic pharmaceutical company in the world and the largest pharmaceutical enterprise in India Founded in 1983, sun Pharma's products mainly involve the treatment of cardiovascular, mental, digestive, respiratory, diabetes and other diseases, ranking the first in India's pharmaceutical sales list in 2018 Since 2017, sun pharmaceutical has declared several APIs, such as mesalazine, ciprofloxacin, cilastatin sodium, imipenem, bicalutamide, atorvastatin calcium, metoprolol tartrate, pregabalin, etc In 2017, sun pharmaceutical was approved as fexofenadine hydrochloride tablets, but this product was launched by Ranbaxy in 2009 Sun pharmaceutical was listed in isosorbide mononitrate sustained-release tablets in 2006 and latanoprost in 2009 It is one of the few companies in China that import preparations In June 2019, kangzhe pharmaceutical's wholly-owned subsidiary and sun pharmaceutical's wholly-owned subsidiary cooperated with tildrakizumab (an innovative biological treatment product for psoriasis and psoriatic arthritis) and 0.09% cyclosporin A eye drops (an innovative treatment product for dry eyes) Kangzhe Pharmaceutical Co., Ltd has obtained the exclusive and sublicensable license for the development and commercialization of the two products in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan) for 15 years from the first marketing of the products in the region In August of the same year, kangzhe pharmaceutical once again signed a license agreement with sunpharma on its seven generic pharmaceutical products through its wholly-owned subsidiary, and obtained the exclusive and sublicensable right to develop and commercialize the products in mainland China according to the intellectual property rights and registration documents of sunpharma for 20 years from the initial listing and sale of the products in the region 5 Glenmark pharmaceuticals was founded in 1977 and headquartered in Mumbai Its main research and development fields are the discovery of new molecular entities (nces) and new biological macromolecular entities (NBES), especially the research and development of new drugs and similar biological drugs in the fields of cancer, skin diseases and respiratory diseases It has a place in the market for branded generic drugs in emerging economies (India, Russia and Africa) The most familiar treatment for prostate cancer in China is abitrone Glenmark Before that, the products of pharmaceutical entering China were mainly raw materials, including fluconazole, lecardine hydrochloride and perindopril TERT butylamine salt, which introduced fluconazole with Hainan Hanguang; cooperated with Guangzhou Tonghui to introduce perindopril TERT butylamine salt and topiramate, but the latter was not approved; cooperated with shandongdanhong to cooperate with tofacib citrate; cooperated with Zhaoke pharmaceutical to cooperate with lecardine hydrochloride; cooperated with Yuanda Medical Co., Ltd Drug cooperation: olotadine hydrochloride; cooperation with Sichuan kered: minapram hydrochloride; cooperation with Dongguan East Sunshine: adapalin However, glenmark has not yet recorded the products on API platform In August 2018, Chinese pharmaceutical companies and platinum pharmaceutical reached an exclusive license agreement with glenmark pharmaceutical to develop, manufacture and commercialize antibody drug gbr1302 in Greater China Gbr1302 is a clinical stage based on glenmarkbeat (specific engagement by antibodies based on the T cell receiver) technology platform, targeting the bispecific antibodies of HER2 and CD3 , which will be developed in Greater China for the treatment of HER2 positive cancer (including breast cancer, gastric cancer, etc.), in addition to the royalty, this exclusive license agreement has a potential value of more than $120 million in milestone payments and sales sharing On July 2, 2019, hisic announced that its subsidiary Sichuan hisic Pharmaceutical Co., Ltd had recently signed a cooperation agreement with Indian glenmark pharmaceutical on aripitan capsule According to the cooperation agreement, glenmark Pharma exclusively manufactures and supplies the product for Hisense, and Hisense purchases the product exclusively from glenmark Pharma, and uses the product for commercialization in mainland China HISCO is responsible for the registration, application and sales of the product in mainland China At present, Hisense has not started to apply for registration in China The total consideration of this transaction is US $400000, and hisilico will pay US $200000 in advance after signing the contract, and another US $200000 after obtaining the listing approval of China National Drug Administration After the product has been approved and put on the market successfully, Hisense will issue the product purchase order according to the delivery cycle and minimum order quantity stipulated in the agreement 6 Reddy's laboratories was founded in 1984 to produce high quality APIs to India In 1987, the company started the operation of pharmaceutical products, and after growing into a well-known enterprise in the Indian pharmaceutical market, it moved towards internationalization in 1991 Its company has reached US $200 million and is involved in almost all diseases around the world As early as 2000, the pharmaceutical company and Canada dragon lamp group, Kunshan Shuanghe Pharmaceutical Co., Ltd established a tripartite joint venture in Kunshan, Jiangsu Province Kunshan dragon lamp Ruidi Pharmaceutical Co., Ltd The products declared by Kunshan longdengruidi Pharmaceutical Co., Ltd include omeprazole enteric coated capsules, benbromarone capsules, bezafibrate and tablets, metformin glibenclamide tablets (I) and (II), famotidine tablets, fluconazole capsules, gifeprozil capsules, ramipril and tablets, linalenate and cream, dopanil maleate